TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01930240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRIA-662
Description: 1-MNA Chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind placebo
Study: NCT01031199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FEDAA1106 (BAY85-8101)
Description: MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
Study: NCT00229697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Study: NCT03180333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PNA placebo
Study: NCT04042597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: anlotinib was given at a fixed dose of 12mg D1-14 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib Hydrochloride
Description: anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
Study: NCT04685980

Intervention type: PROCEDURE
Intervention: spinal anaesthesia with local anaesthetic and intrathecal morphine
Description: Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine

Intervention type: PROCEDURE
Intervention: spinal anaesthesia with local anaesthetic and intrathecal morphine
Description: Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
Study: NCT01527591

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal Conjugate Vaccine 13 (PCV13)
Description: A single intramuscular dose of 0.5 mL.
Study: NCT03027518

Intervention type: OTHER
Group type: OTHER
Intervention: WILD 5 Wellness
Description: Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.

Intervention type: OTHER
Group type: OTHER
Intervention: WILD 5 Wellness
Description: Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
Study: NCT01373008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)
Description: Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
Study: NCT01031199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FEDAA1106 (BAY85-8101)
Description: Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
Study: NCT00964262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR Exenatide (PT302)
Description: 0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Plcacebo of each doasage, single subcutanoeus injection
Study: NCT00612339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin and Temozolomide
Description: This is Phase II study with the combination of Avastin \& Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin \& Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI \& repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy \& requests discontinuation, patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT therapy, \& future therapy after 4 cycles will be at discretion of patient \& treating physicians.
Study: NCT00740363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Once daily sitagliptin. If GFR\>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
Study: NCT01373008

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)
Description: Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
Study: NCT01831466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib ointment 20 mg/g
Description: tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib ointment 10 mg/g
Description: tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ointment (vehicle)
Description: placebo ointment (vehicle) BID (twice daily) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib ointment 20 mg/g
Description: tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib ointment 10 mg/g
Description: tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ointment (vehicle)
Description: placebo ointment (vehicle) QD (once daily) for 12 weeks
Study: NCT03601065

Intervention type: OTHER
Intervention: Videos of polyps, resection of polyps
Description: Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
Study: NCT06291337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhibition of Sweet Taste by Ibuprofen Oral Rinses
Description: Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhibition of Sweet Taste by Naproxen Oral Rinses
Description: Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
Study: NCT02282072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation：PINS Stimulation System

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation：PINS Stimulation System
Study: NCT00475085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: Given orally or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron hydrochloride
Description: Given orally or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron hydrochloride
Description: Given orally or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron hydrochloride
Description: Given orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given orally or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prochlorperazine
Description: Given orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prochlorperazine
Description: Given orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prochlorperazine
Description: Given orally or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT04249297

Intervention type: DRUG
Intervention: Duphaston® (Dydrogesteron)
Description: No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
Study: NCT04368299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Videoconferencing for follow-up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard in-person outpatient follow-up
Study: NCT04087941

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VM-202
Description: VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM-202
Description: VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
Study: NCT03593486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Pulsed EMF
Description: Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
Study: NCT02010242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GKT137831
Description: 1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
Study: NCT03939338

Intervention type: OTHER
Intervention: Treg levels and CMR results
Description: This is an observational study. Exposure: Different Treg levels and CMR results.
Study: NCT03102515

Intervention type: DRUG
Group type: OTHER
Intervention: USG-TAP block

Intervention type: DRUG
Group type: OTHER
Intervention: USG-TAP block

Intervention type: DRUG
Group type: OTHER
Intervention: CIC

Intervention type: DRUG
Group type: OTHER
Intervention: CIC
Study: NCT00293228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid (5mg per kg up to 300 mg daily for 6 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid (5mg per kg up to 300 mg daily for 6 months)
Study: NCT00740363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: No active sitagliptin treatment for 4 weeks
Study: NCT00293228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid (5mg per kg up to 300 mg daily for 6 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid (5mg per kg up to 300 mg daily for 6 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: isoniazid (5mg per kg up to 300 mg daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid
Description: isoniazid (5mg per kg up to 300 mg daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: isoniazid (5mg per kg up to 300 mg daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid
Description: isoniazid (5mg per kg up to 300 mg daily for 6 months
Study: NCT00851890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: 50 mg capsules
Study: NCT00786500

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gynostemma pentaphyllum tea
Description: 3 grams twice daily, orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: 3 grams twice daily, orally
Study: NCT03473977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
Study: NCT00851890

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-333
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
Study: NCT03687775

Intervention type: OTHER
Intervention: Stability assessment
Description: Qualitative and quantitative stability assessment
Study: NCT02134561

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychological interview

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study

Intervention type: OTHER
Group type: OTHER
Intervention: cognitive tests

Intervention type: OTHER
Group type: OTHER
Intervention: neurological tests
Study: NCT02457689

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GTU®-MultiHIV B Clade Vaccine
Description: The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GTU®-MultiHIV B Clade Vaccine
Description: The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride BP
Description: For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride BP
Description: For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
Study: NCT03519724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Reversal of deep NMB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Reversal of moderate NMB
Study: NCT00945568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoleban EN
Description: benefits of this drug for patients who undergoing liver resection for HCC

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Aminoleban EN
Description: benefits of this drug for patients who undergoing liver resection for HCC
Study: NCT02628600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAI 590 mg
Description: LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAI 590 mg
Description: LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-drug regimen
Description: Multidrug antimycobacterial regimen from study INS-212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-drug regimen
Description: Multidrug antimycobacterial regimen from study INS-212
Study: NCT04635709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback training and interferential therapy
Description: compare the effect of applying both types of devices on the pelvic floor muscles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biofeedback training and interferential therapy
Description: compare the effect of applying both types of devices on the pelvic floor muscles
Study: NCT04538300

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abramowitz Emesis Score
Description: Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abramowitz Emesis Score
Description: Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Degree of nausea
Description: Degree of postoperative nausea was evaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Degree of nausea
Description: Degree of postoperative nausea was evaluated.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Observer's Assessment of Alertness/Sedation Scale
Description: Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Observer's Assessment of Alertness/Sedation Scale
Description: Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
Study: NCT00475371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC253 Inhalation Powder
Description: Inhalation powder
Study: NCT03825497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotion of activity during and after hospitalization
Description: 1) a welcome folder encouraging physical activity; 2) encouragement to use a walk path established in the ward; 3) encouragement to use posters containing exercise suggestions;4) prescription of a walk-plan for in-hospital use; 5) encouragement to pick up clothes and beverages by oneself; 6) prescription of a walk-plan at discharge for at home use 7) follow-up on walk plan after discharge by municipality
Study: NCT04434105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platlet rich plasma (PRP)
Description: Platelet-rich plasma (PRP) promotes angiogenesis, neurogenesis, and nerve regeneration, also it could reduce swelling and inflammation of the flexor tenosynovitis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 40 mg triamcinolone acetonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT01997281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fiber-enriched cereal
Description: * provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~* one serving of steamed egg is added for dinner and breakfast

Intervention type: OTHER
Group type: OTHER
Intervention: conventional cereal
Description: * provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~* one serving (40g) of steamed egg is added for dinner and breakfast
Study: NCT01288586

Intervention type: DEVICE
Intervention: Scandinavian Total Ankle Replacement System (STAR Ankle)
Description: Total Ankle Replacement
Study: NCT03037567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Weight Watchers plan
Description: Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
Study: NCT02226419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Break in L-carnitine treatment
Description: Levocarnitine oral tablet supplement at individual doses
Study: NCT04212936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure
Description: Limited intraabdominal pressure during laparoscopic cholecystectomy between 8 and 10 mmHg.
Study: NCT03370198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
Study: NCT02471209

Intervention type: DRUG
Intervention: Sevoflurane
Description: general anesthesia with 2% followed by 3% sevoflurane